Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

NCT07219576 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT07219576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition
Lead sponsor
University of California, San Diego
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 8, 2026
Completion date
December 31, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung carcinoma, renal cell carcinoma